Lung cancer: open trials in Japan

• NCT05384626

  A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

  Trial Treatment · Phase 1/2 · Nuvalent Inc.

  Kanagawa Cancer Center, Kanagawa · Okayama University Hospital, Okayama · Kindai University Hospital, Osaka · Shizuoka Cancer Center, Shizuoka · Cancer Institute Hospital of JFCR, Tokyo · National Cancer Center Hospital, Tokyo · Wakayama Medical University Hospital, Wakayama

  Registry updated 2026-11-06

• NCT05920356

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  Trial Treatment · Phase 3 · Amgen

  Juntendo University Hospital, Bunkyo-ku · Saitama Cancer Center, Bunkyo-ku · Chiba Cancer Center, Chiba · National Hospital Organization Kyushu Cancer Center, Fukuoka · Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers, Fukuyama-shi · Kansai Medical University Hospital, Hirakata-shi · Hirosaki University Hospital, Hirosaki-shi · Kanazawa University Hospital, Kanazawa · National Cancer Center Hospital East, Kashiwa-shi · St. Marianna University Hospital, Kawasaki-shi · Hospital of the University of Occupational and Environmental Health, Japan, Kitakyushu-shi · Kobe Minimally Invasive Cancer Center, Kobe · The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku · Kurume University Hospital, Kurume-shi · Kyoto University Hospital, Kyoto · National Hospital Organization Shikoku Cancer Center, Matsuyama · Nagoya University Hospital, Nagoya · Miyagi Cancer Center, Natori-shi · Niigata Cancer Center Hospital, Niigata · Okayama University Hospital, Okayama · Osaka International Cancer Institute, Osaka · Kindai University Hospital, Sakai-shi · National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-Shi · National Hospital Organization Hokkaido Cancer Center, Sapporo · Sendai Kousei Hospital, Sendai · Dokkyo Medical University Hospital, Shimotsuga-gun · Shizuoka Cancer Center, Sunto-gun · Takarazuka City Hospital, Takarazuka-shi · Ehime University Hospital, Toon-shi · National Hospital Organization Yamaguchi-Ube Medical Center, Ube-shi · Wakayama Medical University Hospital, Wakayama · Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama · Tottori University Hospital, Yonago-shi

  Registry updated 2026-11-06

• NCT06881784

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  Trial Treatment · Phase 3 · Revolution Medicines, Inc.

  Hyogo Cancer Center, Akashi · National Cancer Center Hospital, Chuo Ku · Saitama Medical University International Medical Center, Hidaka · Kansai Medical University Hospital, Hirakata-shi · Kanazawa University Hospital, Kanazawa · Nara Medical University Hospital, Kashihara-shi · National Cancer Center Hospital East, Kashiwa-shi · Cancer Institute Hospital of JFCR, Koto-Ku · University Hospital Kyoto Prefectural University of Medicine, Kyoto · NHO Himeji Medical Center, Matsuyama · NHO Shikoku Cancer Center, Matsuyama · Shizuoka Cancer Center, Nagaizumi-chō · Aichi Cancer Center Hospital, Nagoya · Niigata Cancer Center, Niigata · Kindai University Hospital, Osakasayama-Shi · Kitasato University Hospital, Sagamihara · National Hospital Organization Hokkaido Cancer Center, Sapporo · Tohoku University Hospital, Sendai · Sendai Kousei Hospital, Sendai · Fujita Health University Hospital, Toyoake-shi · Wakayama Medical University Hospital, Wakayama · Kanagawa Cancer Center, Yokohama

  Registry updated 2026-11-06

• NCT05789082

  A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

  Trial Treatment · Phase 1/2 · Hoffmann-La Roche

  National Cancer Center Hospital East, Chiba · Kindai University Hospital, Osaka · National Cancer Center Hospital, Tokyo · The Cancer Institute Hospital of JFCR, Tokyo · Wakayama Medical University Hospital, Wakayama

  Registry updated 2026-11-05

• NCT06793215

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  Trial Treatment · Phase 3 · Hoffmann-La Roche

  Fujita Health University Hospital, Aichi · Kurume University Hospital, Fukuoka · Kyushu University Hospital, Fukuoka · Hakodate Goryoukaku Hospital, Hokkaido · Hyogo Medical University Hospital, Hyōgo · Kagoshima University Hospital, Kagoshima · Kanagawa Cancer Center, Kanagawa · Sendai Kousei Hospital, Miyagi · Niigata University Medical & Dental Hospital, Niigata · Okayama University Hospital, Okayama · Kindai University Hospital, Osaka · Osaka Metropolitan University Hospital, Osaka · Kansai Medical University Hospital, Osaka · Tohoku University Hospital, Sendai · Shizuoka Cancer Center, Shizuoka · The Cancer Institute Hospital of JFCR, Tokyo · Juntendo University Hospital, Tokyo · National Cancer Center Hospital, Tokyo · Tokyo Medical University Hospital, Tokyo · Wakayama Medical University Hospital, Wakayama

  Registry updated 2026-11-05

• NCT07144280

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  Trial Treatment · Phase 3 · Pfizer

  Hyogo Cancer Center, Akashi · National Hospital Organization Beppu Medical Center, Beppu-shi · Nippon Medical School Hospital, Bunkyo-ku · National Hospital Organization Kyushu Cancer Center, Fukuoka · National Hospital Organization Tokyo National Hospital, Kiyose · National Hospital Organization Kochi National Hospital, Kochi · National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure · Kurume University Hospital, Kurume · National Hospital Organization Kyoto Medical Center, Kyoto · Shizuoka Cancer Center, Nagaizumi-chō · National Hospital Organization Okayama Medical Center, Okayama · National Hospital Organization Nagasaki Medical Center, Ōmura · Osaka International Cancer Institute, Osaka · Kindai University Hospital, Sakai · NHO Kinki-Chuo Chest Medical Center, Sakai · Sendai Kousei Hospital, Sendai · The University of Osaka Hospital, Suita · Osaka University Hospital, Suita · Mie Chuo Medical Center, Tsu

  Registry updated 2026-11-05

• NCT07361497

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  Trial Treatment · Phase 3 · Bristol-Myers Squibb

  Tokyo Metropolitan Komagome Hospital, Bunkyo Ku · National Hospital Organization Kyushu Cancer Center, Fukuoka · Hamamatsu University Hospital, Hamamatsu · Saitama Medical University International Medical Center, Hidaka · Kansai Medical University Hospital, Hirakata · Kobe University Hospital, Kobe · Aichi Cancer Center Hospital, Nagoya · Hyogo Medical University Hospital, Nishinomiya · Okayama University Hospital, Okayama · Kitasato University Hospital, Sagamihara · Kindai University Hospital, Sakai · Sendai Kousei Hospital, Sendai · Tohoku University Hospital, Sendai · Kanagawa Cancer Center, Yokohama

  Registry updated 2026-11-05

• NCT05579366

  Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  Trial Treatment · Phase 1/2 · Genmab

  Hyogo Cancer Center, Akashi · Fukushima Medical University Hospital, Fukushima · Saitama Medical University International Medical Center, Hidaka · Cancer Institute Hospital of JFCR, Koto · Shizuoka Cancer Center, Nagaizumi-chō · Gunma Prefectural Cancer Center, Ōta · Sapporo Medical University Hospital, Sapporo · Keio University Hospital, Shinjuku-ku · Yamagata University Hospital, Yamagata

  Registry updated 2026-11-04

• NCT06119581

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  Trial Treatment · Phase 3 · Eli Lilly and Company

  National Hospital Organization Asahikawa Medical Center, Asahikawa · Juntendo University Hospital, Bunkyō City · Tokyo Metropolitan Komagome Hospital, Bunkyō City · National Hospital Organization Kyushu Cancer Center, Fukuoka · Kyushu University Hospital, Fukuoka · Saitama Medical University International Medical Center, Hidaka · Himeji Medical Center, Himeji · Kansai Medical University Hospital, Hirakata · Kanazawa University Hospital, Kanazawa · Ibaraki Prefectural Central Hospital, Kasama · National Cancer Center Hospital East, Kashiwa · Kobe City Medical Center General Hospital, Kobe · Japanese Foundation for Cancer Research, Kōtō City · University Hospital Kyoto Prefectural University of Medicine, Kyoto · National Hospital Organization Shikoku Cancer Center, Matsuyama · Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun · Nagasaki University Hospital, Nagasaki · Aichi Cancer Center Hospital, Nagoya · Miyagi Cancer Center, Natori · Niigata Cancer Center Hospital, Niigata · Okayama University Hospital, Okayama · Kindai University Hospital- Osakasayama Campus, Sakai · National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai · Hokkaido University Hospital, Sapporo · National Hospital Organization Yamaguchi Ube Medical Center, Ube · Tochigi Cancer Center, Utsunomiya · Wakayama Medical University Hospital, Wakayama · Kanagawa Cardiovascular and Respiratory Center, Yokohama · Kanagawa Cancer Center, Yokohama · Tottori University Hospital, Yonago

  Registry updated 2026-11-04

• NCT06400472

  A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  Trial Treatment · Phase 1 · Eli Lilly and Company

  Shizuoka Cancer Center, Shizuoka · National Cancer Center Hospital, Tokyo · Cancer Institute Hospital of JFCR, Tokyo

  Registry updated 2026-11-04

• NCT06452277

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  Trial Treatment · Phase 3 · Bayer

  Nippon Medical School - Nippon Medical School Hospital - Cancer Center, Bunkyo-ku · National Hospital Organization Kyushu Medical Center, Fukuoka · National Hospital Organization Himeji Medical Center, Himeji · Kansai Medical University Hospital, Hirakata · National Cancer Center Hospital East, Kashiwa · Saitama Cancer Center, Kitaadachi · Kobe University Hospital, Kobe · National Hospital Organization Nagoya Medical Center, Nagoya · Niigata Cancer Center Hospital, Niigata · Osaka International Cancer Institute, Osaka · Kitasato University Hospital, Sagamihara · Kindai University Hospital, Sakai · Hokkaido University Hospital, Sapporo · Sendai Kousei Hospital, Sendai · National Hospital Organization-Yamaguchi-Ube Medical Center (Sanyo Hospital), Ube · Tottori University Hospital, Yonago

  Registry updated 2026-11-04

• NCT06465069

  A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  Trial Treatment · Phase 1 · Eli Lilly and Company

  National Cancer Center Hospital, Chūōku · National Cancer Center Hospital East, Kashiwa, Chiba · The Cancer Institute Hospital of JFCR, Kōtō City · Aichi Cancer Center Hospital, Nagoya

  Registry updated 2026-11-04

• NCT06561685

  A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

  Trial Treatment · Phase 1 · Eli Lilly and Company

  National Cancer Center Hospital, Chūōku · National Cancer Center Hospital East, Kashiwa · The Cancer Institute Hospital of JFCR, Kōtō City · Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun

  Registry updated 2026-11-04

• NCT06706076

  A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

  Trial Treatment · Phase 1/2 · BlossomHill Therapeutics

  National Cancer Center Hospital East, Kashiwa · Kindai University Hospital, Osakasayama-Shi · National Cancer Center Hospital, Tsukiji

  Registry updated 2026-11-04

• NCT06890598

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  Trial Treatment · Phase 3 · Eli Lilly and Company

  Juntendo University Hospital, Bunkyō City · Tokyo Metropolitan Komagome Hospital, Bunkyō City · Kyushu University Hospital, Fukuoka · Saitama Medical University International Medical Center, Hidaka · Himeji Medical Center, Himeji · Kansai Medical University Hospital, Hirakata · Kanazawa University Hospital, Kanazawa · National Cancer Center Hospital East, Kashiwa · Kobe Minimally Invasive Cancer Center, Kobe · The Cancer Institute Hospital of JFCR, Kōtō City · University Hospital Kyoto Prefectural University of Medicine, Kyoto · Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun · Aichi Cancer Center Hospital, Nagoya · Miyagi Cancer Center, Natori · Niigata Cancer Center Hospital, Niigata · Kindai University Hospital- Osakasayama Campus, Sakai · NHO Kinki-Chuo Chest Medical Center, Sakai · Hokkaido University Hospital, Sapporo · Wakayama Medical University Hospital, Wakayama · Kanagawa Cancer Center, Yokohama · Kanagawa Cardiovascular and Respiratory Center, Yokohama · Tottori University Hospital, Yonago

  Registry updated 2026-11-04

• NCT07492680

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  Trial Treatment · Phase 2 · Bristol-Myers Squibb

  National Cancer Center Hospital, Chuo Ku

  Registry updated 2026-11-04

• NCT03340506

  Dabrafenib and/or Trametinib Rollover Study

  Trial Treatment · Phase 4 · Novartis Pharmaceuticals

  Chuo Ku · Kashiwa

  Registry updated 2026-11-03

• NCT05498428

  A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  Trial Treatment · Phase 2 · Janssen Research & Development, LLC

  National Hospital Organization Himeji Medical Center, Himeji · Saiseikai Matsusaka Municipal Hospital, Matsusaka · Niigata Cancer Center Hospital, Niigata · Shizuoka Cancer Center, Shizuoka · The Cancer Institute Hospital of JFCR, Tokyo · Wakayama Medical University Hospital, Wakayama

  Registry updated 2026-11-03

• NCT06170788

  Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Tokyo Metropolitan Komagome Hospital (Site 3405), Bunkyo · National Hospital Organization Kyushu Cancer Center (Site 3417), Fukuoka · National Hospital Organization Kyushu Medical Center (Site 3416), Fukuoka · National Hospital Organization Himeji Medical Center (Site 3426), Himeji · Kansai Medical University Hospital (Site 3412), Hirakata · Hirosaki University Hospital (Site 3429), Hirosaki · National Cancer Center Hospital East (Site 3403), Kashiwa · St. Marianna University Hospital (Site 3421), Kawasaki · Cancer Institute Hospital of JFCR (Site 3404), Koto · Saiseikai Kumamoto Hospital (Site 3419), Kumamoto · Kurume University Hospital (Site 3418), Kurume · Saiseikai Matsusaka Municipal Hospital (Site 3422), Matsusaka · National Hospital Organization Shikoku Cancer Center (Site 3415), Matsuyama · Niigata Cancer Center Hospital (Site 3409), Niigata · Osaka Prefectural Hospital Organization Osaka International Cancer Institute (Site 3414), Osaka · Gunma Prefectural Cancer Center (Site 3402), Ōta · Toho University Omori Medical Center (Site 3420), Ōta-ku · Tohoku University Hospital (Site 3424), Sendai · Sendai Kousei Hospital (Site 3400), Sendai · Dokkyo Medical University Hospital (Site 3401), Shimotsugagun · National Center for Global Health and Medicine (Site 3406), Shinjuku · Tokyo Medical University Hospital (Site 3407), Shinjuku · Iwate Medical University Hospital (Site 3428), Shiwa-gun · Shizuoka Cancer Center (Site 3410), Suntogun · Osaka Medical and Pharmaceutical University Hospital (Site 3413), Takatsuki · Fujita Health University Hospital (Site 3411), Toyoake · National Hospital Organization Yamaguchi Ube Medical Center (Site 3423), Ube · National Hospital Organization Ureshino Medical Center (Site 3427), Ureshino · Kanagawa Cancer Center (Site 3408), Yokohama · Yokohama Municipal Citizen's Hospital (Site 3425), Yokohama

  Registry updated 2026-11-03

• NCT07288177

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  Trial Treatment · Phase 2 · Genmab

  National Cancer Center - Tsukiji Campus, Chūō · Kyoto Prefectural University of Medicine, Kyoto · Japan Community Health Care Organization Chukyo Hospital, Nagoya · Kitasato University Hospital, Sagamihara · Saitama Medical University International Medical Center, Saitama · NHO Kinki-Chuo Chest Medical Center, Sakai · Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo · Kanagawa Cardiovascular and Respiratory Center, Yokohama

  Registry updated 2026-11-03

• NCT07566052

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  Trial Treatment · Phase 3 · Astellas Pharma Global Development, Inc.

  Tokyo Metropolitan Hospital, Bunkyo-ku · Kyushu Cancer Center, Fukuoka · Kansai Medical University Hospital, Hirakata · Hiroshima City Hiroshima Citizens Hospital, Hiroshima · Miyagi Cancer Center, Natori-shi · Niigata Cancer Center Hospital, Niigata · Kindai University Hospital, Sakai · Hokkaido University Hospital, Sapporo · Japanese Foundation for Cancer research, Tokyo · Kanagawa Prefectural Hospital - Kanagawa Cancer Center, Yokohama

  Registry updated 2026-11-03

• NCT07660055

  Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

  Trial Treatment · Phase 1 · Novartis Pharmaceuticals

  Kashiwa

  Registry updated 2026-11-03

• NCT06712316

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  Trial Treatment · Phase 2/3 · BioNTech SE

  Ageo Central General Hospital, Ageo · Hyogo Cancer Center, Akashi · Aomori Prefectural Central Hospital, Aomori · Tokyo Metropolitan Komagome Hospital, Bunkyō City · Hamamatsu University Hospital, Chūōku · Funabashi Municipal Medical Center, Funabashi · National Hospital Organization Himeji Medical Center, Himeji · Hiroshima Prefectural Hospital, Hiroshima · Hiroshima University Hospital, Hiroshima · Aso Iizuka Hospital, Iizuka · National Hospital Organization Iwakuni Clinical Center, Iwakuni · Shonan Kamakura General Hospital, Kanagawa · Ishikawa Prefectural Central Hospital, Kanazawa · Social Welfare Organization Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital, Kumamoto · Kurashiki Central Hospital, Kurashiki · Kurume University Hospital, Kurume · Matsusaka Municipal Hospital, Matsusaka · National Hospital Organization Shikoku Cancer Center, Matsuyama · National Hospital Organization Tokyo Medical Center, Meguro City · Dokkyo Medical University Hospital, Mibu · Iwate Medical University Hospital, Morioka · Shizuoka Cancer Center, Nagaizumi-chō · Nagasaki University Hospital, Nagasaki · National Hospital Organization Nagoya Medical Center, Nagoya · Japan Community Healthcare Organization Chukyo Hospital, Nagoya · Nagoya University Hospital, Nagoya · Niigata Cancer Center Hospital, Niigata · Hyogo Medical University Hospital, Nishinomiya · Osaka Prefectural Hospital Organization - Osaka International Cancer Institute, Osaka · Saitama Prefectural Cancer Center, Saitama · NHO Kinki-Chuo Chest Medical Center, Sakai · Teine Keijinkai Hospital, Sapporo · Sapporo Minamisanjo Hospital, Sapporo · Sendai Kousei Hospital, Sendai · Shibukawa Medical Center, Shibukawa · Toyama University Hospital, Toyama · Wakayama Medical University Hospital, Wakayama · Yokohama Municipal Citizen's Hospital, Yokohama

  Registry updated 2026-11-02

• NCT07166601

  M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

  Trial Treatment · Phase 1 · EMD Serono Research & Development Institute, Inc.

  National Cancer Center Hospital, Chūōku

  Registry updated 2026-11-02

• NCT07185997

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  Trial Treatment · Phase 3 · ArriVent BioPharma, Inc.

  Hyogo Cancer Center, Akashi-shi · Nippon Medical School Hospital, Bunkyo-ku · Tokyo Metropolitan Komagome Hospital, Bunkyo Ku · National Cancer Center Hospital, Chuo Ku · Kansai Medical University Hospital, Hirakata-shi · National Cancer Center Hospital East, Kashiwa · Kurume University Hospital, Kurume-shi · Aichi Cancer Center, Nagoya · Miyagi Cancer Center, Natori-shi · Niigata Cancer Center Hospital, Niigata · National Hospital Organization Hokkaido Cancer Center, Sapporo · Fujita Health University Hospital, Toyoake

  Registry updated 2026-11-02

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error